We are live on ! Find out more
BPMC

Blueprint Medicines
BPMC

Delisted

BPMC was delisted on the 17th of July, 2025.

Back to rankings

Fund managers haven’t disclosed any holdings of BPMC yet.

BPMC Hedge Fund Activity: Q1 2026 in Review

2 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q1 2026, worth a combined $38.6K — down 99% from $2.57M a quarter earlier.

Fund positioning in BPMC was balanced in Q1 2026: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.

The largest buyer was Kelleher Financial Advisors, opening a new position worth an estimated $38.5K. The largest seller was DekaBank Deutsche Girozentrale, exiting entirely with an estimated $2.57M sold.

  • 2 institutional investors held Blueprint Medicines (BPMC) as of Q1 2026, unchanged from Q4 2025.
  • Funds reported $38.6K of Blueprint Medicines stock for Q1 2026, down 99% quarter-over-quarter.
  • 1 fund opened new Blueprint Medicines positions in Q1 2026 and 1 closed out, a net change of 0 holders.
  • The largest Blueprint Medicines buyer in Q1 2026 was Kelleher Financial Advisors, an estimated $38.5K added.
  • The largest Blueprint Medicines seller in Q1 2026 was DekaBank Deutsche Girozentrale, an estimated $2.57M sold.

Based on aggregated 13F filings for Q1 2026.